The poor prognosis of metastatic pancreatic ductal adenocarcinoma combined with its resistance to conventional treatment such as chemotherapy and radiation necessitate the need for novel therapies. Immunotherapies are widely researched due to the potential for durable response and a favorable toxicity profile. In the current trial, although the immunotherapeutic combination of CY/GVAX+CRS-207 was welltolerated, it did not show a survival benefit over chemotherapy in subjects with previously treated metastatic pancreatic adenocarcinoma. Notably, survival of subjects receiving CRS-207 alone appeared similar to that of subjects treated with chemotherapy. Nevertheless, this trial illustrates the difficulties in conducting randomized trials testing novel agents against a reference therapy in a previouslytreated patient population. Furthermore, immunotherapeutic strategies with novel combinations may be necessary for further development in difficult to treat cancers. 
Introduction
Pancreatic adenocarcinoma is a disease with a high mortality rate and limited effective therapeutic options. Over 80% of pancreatic cancers are unresectable at diagnosis due to the presence of regional or distant disease at diagnosis (1). Even those who undergo potentially curative resection are likely to succumb to the disease within a few years.
The chemotherapeutic combinations FOLFIRINOX (5-fluorouracil/lecovorin, irinotecan, and oxaliplatin) and gemcitabine/nab-paclitaxel for patients with metastatic pancreatic cancer have improved response rates, disease-free survival, and median overal survival (OS) compared to those observed with single-agent chemotherapy. However, outcomes remain poor, at an estimated survival of less than 1 year (2). Only a single combination therapy, liposomal irinotecan with fluorouracil/folinic acid, has been approved for second-line therapy in gemcitabine-treated patients based on prolonged OS over fluorouracil/folinic acid (6.28 vs 4.2 months; NAPOLI-1) (3). As a result, there is an urgent and unmet need to develop more effective therapies for patients with advanced pancreatic cancer with disease progression after first-line therapy.
Immunotherapy carries potential advantages over chemotherapy (e.g. lower toxicity and more durable responses) and recent progress in immunotherapy has occurred for various other malignancies (4-6). While immunotherapy is emerging as a treatment option for some gastrointestinal cancers, activity remains poor in pancreatic cancer, in part due to a relative absence of immune infiltrating effector T cells in the tumor microenvironment (7). Immunotherapy strategies aim to expand tumor-specific T (granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells) followed by CRS-207 improved overall survival (OS) compared to Cy/GVAX alone (10). Low-dose Cy was given to enhance the immune response by depleting regulatory T cells and enhance expansion of effector T cells (11). The study resulted in a median OS of 6.28 months (95% CI, 4.47 to 9.40 months) for patients treated with CRS-207 + Cy/GVAX. In a subset analysis, median OS in patients with > 2 prior regimens was 5.7 months (95% CI, 3.4 to 9.7). In light of these promising results, a Phase 2b randomized, multicenter study was conducted to compare Cy/GVAX + CRS-207 to chemotherapy in patients with metastatic pancreatic cancer (ClinicalTrials.gov ID: NCT02004262). Randomization was stratified by progressive or stable disease status at study entry based on investigator's assessment. There were two cohorts in the study, the primary cohort and the second-line cohort. The primary cohort comprised of patients who had received ≥2 prior lines of therapy, including one gemcitabine-based regimen, specifically in the metastatic disease setting (third-line+). The second-line cohort included patients who had received exactly one prior regimen of chemotherapy for metastatic pancreatic cancer.
Patients and Methods

Study Design
The primary endpoint was to compare OS of Arm A to Arm C in the primary cohort (third-line+). Secondary endpoints were safety, OS in the primary cohort between Arm B and Arm C, and other efficacy, immunological, biomarker, and safety parameters in Arm A vs. Arm B. Exploratory endpoints included but were not limited to tumor responses using RECIST v1.1 and safety and survival analyses in the second-line cohort. This study was performed in accordance with Good Clinical Practice and the Declaration of Helsinki. The study was reviewed by local Institutional Review Boards, biosafety committees, the US Food and Drug Administration, and the National Institutes of Health Recombinant DNA Advisory Committee. Interim data were reviewed by an independent data monitoring committee (DMC), including an interim analysis of futility.
Written informed consent was obtained from all patients.
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Patients
Eligible patients had histologically-proven, previously treated, metastatic adenocarcinoma of the pancreas, were ≥18 years old, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function.
Patients were excluded if they had brain metastases, major artificial implants or devices that could not be easily removed (portacaths and biliary stents were allowed), hepatic cirrhosis or clinical or radiographic ascites, thromboembolic disease within 2 months, HIV, hepatitis B or C, or autoimmune disease.
Treatment
In Arms A and B, one treatment course was 20 weeks, consisting of six study drug 
Assessments
Physical examinations, complete blood count and chemistries were performed prior to each treatment and the day after CRS-207 infusions. Safety was assessed in the full analysis set (FAS) by reported adverse events (AEs). Imaging was performed at baseline, week 10 and week 20. Tumor response was determined by investigator assessment using RECIST v1.1. Immune-related response was assessed in patients administered CRS-207 (Arms A and B) using irRC(12).
Statistical Analysis
The primary efficacy analysis compared OS based on the log-rank test for Cy/GVAX and CRS-207 versus chemotherapy in the primary cohort using the ITT population, which included all randomized patients. Secondary analyses were performed on the FAS. Power was computed for a 2-stage group sequential design with a single interim analysis for futility using an overall one-sided type I error rate of 0.15. The amount of alpha spent (1-sided) for the interim analysis was 0.0015. Accordingly, the 1-sided pvalue for the final analysis needed to be <0.1499 in order to reject the null hypothesis of equal survival. If the mOS in Arm A was 6 months and that for Arm C was 4 months, an estimated 45 and 48 deaths for treatment Arms A and C, respectively at the time of the primary analysis would provide more than 80% power to detect a HR of 0.67 using the log-rank test. A sample size of at least 150 treated patients (50 treated per Arm) was targeted to achieve the desired power in both the ITT and FAS populations. Assuming that the survival distribution of Arm B was similar to Arm A, the primary analysis was planned to occur at 138 deaths in the FAS for the primary cohort (estimated at 45, 45, and 48 deaths for Treatment Arms A, B and C, respectively). A final analysis was performed using all available trial data when the study was completed, which occurred after all patients had a minimum follow-up of at least 12 months or died. This paper reports the results of the final analysis. An additional 90 patients (30 per arm), would be treated in an exploratory cohort of second-line patients.
Kaplan Meier method was used to estimate median survival and 95% CIs for mOS and PFS. The log-rank test was used to compare OS and PFS between treatment arms. The Cox proportional hazards model and Wald statistics were used to estimate HRs and CIs. Overall survival and progression-free survival were calculated from the date of randomization until the date of death and date of disease progression or death, respectively. PFS and tumor response summaries are based on the FAS.
Results
Study population, demographics and baseline characteristics
Initially, 513 patients were assessed for eligibility. After screening, during which 210 (41%) patients were excluded, 303 patients across 21 sites in the US and Canada were Demographics and baseline characteristics in the FAS are summarized in Table   1 . In the primary and second-line cohorts, 91.1% and 87.9% of patients, respectively, had progressive disease upon enrollment. Numerically, more patients in Arm B had lung-only metastases, whereas more patients in Arm C had undergone primary tumor resection and had liver metastases (Supplementary Table 1 in Figure 4 . Chemotherapy arm performed better in patients 65 years and younger. In those with stable disease prior to study entry, Arms A and B were favored although the absolute numbers were small.
Second-line cohort
Twenty-nine, 31, and 30 patients were randomized to Arms A, B, and C, respectively (ITT population). The median OS was 4.3, 4.1, and 9.1 months in Arm A, Arm B, and Arm C, respectively. The FAS included 26, 29, and 11 patients in Arms A, B, and C, respectively. Again, these numbers reflect the disproportionate drop-out among Arm C patients (63.3%). The median OS in the FAS was 4.6, 4.0, and 6.9 months in Arms A, B, and C, respectively.
There was no statistically significant difference in PFS between Arms A and C, with median of 2.4 months in each arm, as evaluated in the FAS. Similar to the primary cohort, progressive disease was the BOR for the majority of patients in all treatment arms. One subject had a partial response (9.1%) in chemotherapy arm. Disease control rates were 23.1%, 20.7%, and 18.2% in Arms A, B, and C respectively.
Safety
Safety evaluations were performed in the FAS. All treatments were generally welltolerated, with <5% of patients reporting serious adverse events (SAE) related to study treatment. There were no treatment-related deaths. The treatment-related AE profile was similar to prior experience in the experimental arms and consisted mainly of low grade adverse events of pyrexia, chills, fatigue and nausea in all study arms ( 
There were four related, unexpected SAEs reported: confusional state, hypoxia, hypertension and bacteremia.
Serious treatment-emergent AEs were reported for 46.8%, 36.8% and 27.8% of patients in Arm A, B, and C, respectively. Across all patients, the most frequently reported SAE other than disease progression (8.5%) was abdominal pain (4.3%), which was not considered related to the study drug. Overall, 13.2% of patients reported an AE leading to death, none of which was related to the study drugs. The incidence of deaths occuring up until data cutoff was 17%, 9.2% and 5.6% in Arms A, B, and C, respectively, with the primary cause of death being progressive disease. One subject in Arm B reported a SAE of Listeria bacteremia, occurring after the final CRS-207 administration, which was deemed treatment-related by the investigator. The infection resolved after completing antibiotics and subsequent cultures were negative; the patient continued in the follow-up portion of the study.
Neutrophil/lymphocyte ratio
In a post-hoc, pooled analysis of the primary and second-line cohorts, the baseline Table 1 ).
Discussion
Research.
on
Despite the emergence of more effective chemotherapeutic combinations, the prognosis of metastatic pancreatic ductal adenocarcinoma remains poor, with a median OS of about one year and a 5-year survival rate of <5%(2,13). Once metastatic pancreatic cancer progresses on first-line chemotherapy, prognosis is dismal and treatment options are even more limited. Novel therapies are therefore greatly needed, and immunotherapy has become a focus of investigation due to its favorable toxicity profile and the potential for durable response.
In the current trial, the immunotherapeutic combination of CY/GVAX+CRS-207 was well-tolerated, but did not improve survival over standard chemotherapy.
Nevertheless, some important observations drawn from this trial may guide the process of developing cancer immunotherapeutic agents and designing trials to compare conventional and novel therapies. Identification of the study population was based on a subset analysis from a prior randomized Phase 2a study(10) that suggested benefit of Cy/GVAX + CRS-207 over Cy/GVAX alone as third-line therapy for pancreatic cancer.
Lines of therapy were retrospectively calculated, which produced artificial subsets, as regimens can be given in different stages of disease. In the current study, a prior line of therapy referred to chemotherapy administered specifically for metastatic disease. select for patients with favorable disease biology, (i.e. slower growth kinetics and ongoing response or stability with standard chemotherapy). Compared to the prior study, patients on the current study had higher CA 19-9 levels, higher rates of poorly differentiated tumors, and higher rates of liver involvement, all of which may have influenced the poorer outcomes. However, these poor prognostic factors reflect the realworld status of pancreatic cancer patients upon presentation. Baseline NLR has been reported to correlate with prognosis. In our study cohort, a baseline NLR ≤5 correlated with improved survival in a pooled analysis, consistent with previous studies (14) . Posthoc generated Gustave Roussy Immune score (GRIm) was also well-balanced between study cohorts, corroborating the NLR results. In Arm A, 26%, 16.4% and 2.7% of subjects had GRIm scores of 1, 2, and 3, respectively, compared to 34.3%, 13.4%, 3%
in Arm B, and 34,7%, 13.9%, and 1.4% in Arm C, respectively.
A disproportionate number of patients in the single-agent chemotherapy arm discontinued after randomization and prior to first dose (40% in the primary cohort, 63% in the 2nd-line cohort). Presumably, these patients, who had already failed multiple lines of chemotherapy, withdrew upon randomization to receive single-agent chemotherapy in order to pursue more aggressive and novel options. This is in contrast to the NAPOLI-1 trial, which was a global study where 90% of patients randomized to the fluorouracil/folinic acid arm received study assigned treatment despite 70% of these patients having received only ≤1 prior therapy for metastatic disease(3). In this study, 21%, 37%, and 49% of patients in Arms A, B, and C of the primary cohort went on to receive subsequent lines of therapy and 67% of the time these were combination chemotherapy regimens, indicating that these patients may have been more accepting result, emerging agents that inhibit immunosuppressive pathways such as indoleamine 2,3-dioxygenase (IDO) and adenosine, as well as ones that activate stimulatory pathways, such as OX40 agonists, are actively being developed and incorporated into novel immunotherapeutic combinations (21, 22) .
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